Effect of inhaled corticosteroids on bone density in patients with asthma
Monday, March 5, 2018
South Hall A2 (Convention Center)
Hiroyoshi Watanabe, Kumiya Sugiyama, Hajime Arifuku, Shingo Tokita, Hirokuni Hirata, Yasutsugu Fukushima
RATIONALE: Inhaled corticosteroids (ICS) are a safe treatment for asthma and can be used during pregnancy. However, at higher doses, ICS have been reported to inhibit adrenocortical function. This study aimed to evaluate the effect of ICS on bone density in adult patients with asthma.

METHODS: Ultrasonic bone densitometry was performed at the radius for 1 year in 41 patients (14 men, 27 women, mean age 61.6 years) who were receiving ICS for asthma.

RESULTS: At baseline, the mean thickness of the radius was 12.4 mm, the age-matched reading was 101.3%, and the young-normal reading was 91.6%; the respective mean values for cortical bone were 3.53 mm, 103.5%, and 82.2%. The mean density of cancellous bone was 167 mg/cm3 and the age-matched and young-normal readings were 101.4%, and 77.0%, respectively. After 1 year, the respective values at the radius were 12.6 mm, 101.3%, and 91.1%; those for cortical bone were 3.49 mm, 103.9%, and 81.0%; and those for cancellous bone were 163 mg/cm3, 100.8%, and 75.3%. There were no significant changes in any of the above bone density parameters during the study. There was no significant correlation between dose of ICS and changes in bone density.

CONCLUSIONS: In the entire study population, ICS were safe and not associated with an increased risk of osteoporosis. However, there was a decrease in mean bone density, so we are presently evaluating differences in bone density by corticosteroid type and patient background. We will present our final results at the 2018 AAAAI/WAO Joint Congress.